Literature DB >> 12192559

Sarcoma tumor FDG uptake measured by PET and patient outcome: a retrospective analysis.

Janet F Eary1, Finbarr O'Sullivan, Yudi Powitan, Kingshuk Roy Chandhury, Cheryl Vernon, James D Bruckner, Ernest U Conrad.   

Abstract

In a retrospective analysis of patients with sarcoma who underwent fluorodeoxyglucose positron emission tomography (FDG PET) imaging, tumor maximum FDG uptake was analyzed for ability to predict patient survival and disease-free interval. Two hundred and nine patients with sarcoma were imaged prior to treatment with neoadjuvant chemotherapy or resection. Tumor FDG uptake expressed as maximum standard uptake value (SUV(max)) was compared with disease-free and overall survival. A multivariate Cox regression analysis was applied to examine the role of SUV(max) in predicting time to death or disease progression, after adjusting for standard clinical prognostic factors. The multivariate analyses showed that the SUV(max) information is a statistically significant independent predictor of patient survival. Tumors with larger SUV(max) have a significantly poorer prognosis. This retrospective analysis indicates that the sarcoma tumor SUV(max) value determined by PET is an independent predictor of survival and disease progression.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12192559     DOI: 10.1007/s00259-002-0859-5

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  59 in total

Review 1.  Clinical applications of molecular imaging in sarcoma evaluation.

Authors:  Rodney J Hicks; Guy C Toner; Peter F M Choong
Journal:  Cancer Imaging       Date:  2005-06-21       Impact factor: 3.909

2.  Prognostic value of baseline [18F] fluorodeoxyglucose positron emission tomography and 99mTc-MDP bone scan in progressing metastatic prostate cancer.

Authors:  Gustavo S P Meirelles; Heiko Schöder; Gregory C Ravizzini; Mithat Gönen; Josef J Fox; John Humm; Michael J Morris; Howard I Scher; Steven M Larson
Journal:  Clin Cancer Res       Date:  2010-10-25       Impact factor: 12.531

Review 3.  Molecular imaging research in the outcomes era: measuring outcomes for individualized cancer therapy.

Authors:  David A Mankoff; Finbarr O'Sullivan; William E Barlow; Kenneth A Krohn
Journal:  Acad Radiol       Date:  2007-04       Impact factor: 3.173

4.  Soft tissue sarcoma clinical practice guidelines in oncology.

Authors:  George D Demetri; Laurence H Baker; Derrick Beech; Robert Benjamin; Ephraim S Casper; Ernest U Conrad; Thomas F DeLaney; David S Ettinger; Martin J Heslin; Ray J Hutchinson; Krystyna Kiel; William G Kraybill; G Douglas Letson; James Neff; Richard J O'Donnell; I Benjamin Paz; Raphael E Pollock; R Lor Randall; Karen D Schupak; Douglas S Tyler; Margaret von Mehren; Jeffrey Wayne
Journal:  J Natl Compr Canc Netw       Date:  2005-03       Impact factor: 11.908

5.  18F-FDG PET response to neoadjuvant chemotherapy for Ewing sarcoma and osteosarcoma are different.

Authors:  Louie L Gaston; Claudia Di Bella; John Slavin; Rodney J Hicks; Peter F M Choong
Journal:  Skeletal Radiol       Date:  2011-02-06       Impact factor: 2.199

6.  Sarcoma mid-therapy [F-18]fluorodeoxyglucose positron emission tomography (FDG PET) and patient outcome.

Authors:  Janet F Eary; Ernest U Conrad; Janet O'Sullivan; Douglas S Hawkins; Scott M Schuetze; Finbarr O'Sullivan
Journal:  J Bone Joint Surg Am       Date:  2014-01-15       Impact factor: 5.284

7.  Spatial heterogeneity in sarcoma 18F-FDG uptake as a predictor of patient outcome.

Authors:  Janet F Eary; Finbarr O'Sullivan; Janet O'Sullivan; Ernest U Conrad
Journal:  J Nucl Med       Date:  2008-11-07       Impact factor: 10.057

8.  Solitary fibrous tumor of the abdominal wall.

Authors:  Kazuhiro Migita; Akihiko Watanabe; Kenji Nakagawa; Takao Ohyama; Susumu Sekigawa
Journal:  Int J Clin Oncol       Date:  2009-12-05       Impact factor: 3.402

9.  [F-18]-fluorodeoxy-D-glucose-positron emission tomography response is associated with outcome for extremity osteosarcoma in children and young adults.

Authors:  Douglas S Hawkins; Ernest U Conrad; James E Butrynski; Scott M Schuetze; Janet F Eary
Journal:  Cancer       Date:  2009-08-01       Impact factor: 6.860

10.  Fluorodeoxyglucose positron emission tomography in leiomyosarcoma: imaging characteristics.

Authors:  Stephanie E W Punt; Janet F Eary; Janet O'Sullivan; Ernest U Conrad
Journal:  Nucl Med Commun       Date:  2009-07       Impact factor: 1.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.